邢唷> 欹餜%Objbj8lxxF <<8,Lz$I~ H﹜珁珁珁珁珁珁6|貇f珁!珁x蘺.﹜﹜Mu峹皯X諱鵺J晊鈟0zCxJ>>峹>峹珁珁z><K: D桍N1-D崺R啒遅魦f駛噀 Scope of the Research Supported under this FOA This FOA will support studies in the following areas of allergy, immunology, and infectious diseases including HIV/AIDS and its co-morbidities and co-infections, mental health, and selected neurological disorders. NIAID-營mmunology (non-HIV/AIDS): Host immune response and/or regulation and/or immunopathogenesis of the inflammatory effector response to microbial and/or viral infection. Additionally, studies that elucidate the underlying mechanisms that result in immune memory and protection in response to vaccination. Topics of interest relevant to immunity to infection and/or vaccination include, but are not limited to: Differentiation and activation of innate and adaptive immune cells and signaling pathways; Positive and negative regulation of inflammation; Mechanisms by which the innate immune system directs subsequent adaptive immune responses; Generation and maintenance of effector and memory antigen-specific T and B lymphocytes; Generation and maintenance of anti-viral effector innate lymphocytes; Regulation of differentiation and maintenance of effector and memory antigen-specific T and B lymphocytes; Migration of na飗e, memory and effector cells during the induction and effector phases of immune responses and their therapeutic modulation; Generation, differentiation and maintenance of tissue-resident antigen-specific lymphocytes; Responses of tissue-resident lymphocytes to microbial and/or viral infections; Regulation of antibody production and mechanisms of antibody-mediated protection Definition of biomarkers of protective immune responses; Characterization of innate and adaptive mucosal immune responses; Relationship between mucosal immunity and the development of, or protection from, autoimmune disease; Mechanisms of immune-mediated pathogenesis triggered by responses to microbial and/or viral infection; Effect of viral and microbial infections, and environmental pollutants on systemic/regional innate immunity and epithelial/mucosa functions and their contribution to the pathogenesis of asthma, allergic diseases, or autoimmune diseases, and the relationship to commensal microbiota. NIAID - Infectious Diseases (non-HIV/AIDS): Research on infectious diseases (non-HIV/AIDS) should focus on malaria, tuberculosis, dengue fever, enterovirus 71, rabies, schistosomiasis, measles, hepatitis, or influenza and include one of the following areas: Antimicrobial resistance, including mechanisms of resistance; Resistance in disease vectors; Immune responses to infectious diseases or vaccines, including the role of immune responses in pathogenesis; Molecular characteristics of innate immunity in acute or chronic infections and strategies for modulation of the immune responses. NCI - Cancer:Applications should be focused in the following areas: Genomics/Proteomics (e.g., collaborative research leveraging proteomic data publicly released by NCI抯 Clinical Proteomics Tumor Analysis Consortium [CPTAC]) that has been analyzed as part of The Cancer Genome Atlas (TCGA)); Nanotechnology (e.g., collaborative research focused on translating genomic targets into cancer therapeutics using nanotechnology and studies on structure-activity relationships in nanomaterials and their safety); Immunotherapy/ new immune inhibitory receptors/co-inhibitory molecules in tumor progress; Liver cancer studies as a result of carcinogen exposure, high fat diets, or high alcohol intake; DNA damage networks as a target for cancer cells; synthetic biology studies of engineered cells to study biological networks; and the effects of lipid addiction on tumor cells. NCI Priorities.燱ithin the areas of cancer, the specific priorities for this FOA include the following aspects: Genomics/Epigenomics/Transcriptomics (including Epitranscriptomics)/Proteomics Mining/leveraging of TCGA data or proposed work to identify and understand genomic landscape of various cancer types梪nderstanding the role(s) of genes, non-coding RNAs, and gene products in tumorigenesis, progression, and metastasis. CPTAC梒oordinated effort to understand molecular basis of cancer by systematically identifying proteins that derive from alterations in cancer genomes. Nanotechnology Collaborative applications that propose the use of nanotechnology to delineate cancer-associated pathways as a means to characterize and functionally validate cancer genomic findings in relevant cell and animal models Applications that propose the use of nanotechnology to enable cancer biomarker discovery and validation. Research directed towards uncovering structure-activity relationship in nanomaterials and correlation between nanomaterial properties and their safety profiles would also be supported by this FOA. Nanotechnology for immunotherapy梐pplication thay propose to characterize the physiological parameters of nanostructures targeting mononuclear phagocyte system, such as monocytes, macrophages and dendritic cells. Delivering agonists by targeting innate immune sensing pathways with nanotechnology to improve antigen presentation. Targeting immune regulatory cells (e.g. tumor-associated macrophages) to ameliorate tumor immunosuppressive microenvironment. Developing immunotherapy with nanotechnology to improve conventional therapies. Cell engineering Approaches using synthetic biology to improve the understanding of biological networks and/or to develop live intelligent agents to test new diagnostic and therapeutic strategies. DNA-damage network as a target in cancer cells Development of molecule tools and imaging and single-cell and single molecule technology to detect induction , expression and de-construction of molecular complexes that are formed in response to genotoxic therapy a variety of human cancers; Characterization and targeting of DNA repair in cancer stem cells and/or quiescent cancer cells in Go or G1; Establishing the role of DNA damage response communication with the microenvironment induced by cancer therapy (e.g., ionizing radiation) and effects such communication has on resistance to treatment and cancer progression in the face of high levels of DNA damage/replication stress; Exhaustive studies to determine synthetic lethal relationships related to cancer-cell defects in DNA repair or DNA replication for range of human cancers and grades. Liver Cancer 桼esearch questions include: Does the cell of origin influence liver tumor type? Do liver cancer stem cells arise and are they found in all liver tumors? What is the role of the hepatic stellate cell in cancer progression? How do individual cell types/stromal components in the microenvironment influence tumor progression. Lipid addiction of cancer cells The effects of dietary fat intake/obesity on the activation of fatty acid synthesis in cancer cells; The effects of lipid droplets on the induction of fibrosis. Novel strategies of cancer immunotherapy Amplification/modification爋f爄mmune effectors(e.g., with燙hinese herbs); Recruitment of immune effectors to the tumor site; Targeting爐umor stromal燾ells; Prevention of side effects. Antigen-based design of cellular effectors (e.g. CTL, NK); Cancer vaccine including DC vaccine; Immune molecule monitoring; New immune inhibitory receptors/co-inhibitory molecules in tumor progress. NIMH - Mental Health: Research focused on systems and cellular neuroscience as they relate to mental disorders, including: Use of non-human primates to study neurobiological processes underlying cognitive, social, and affective behavior; Use of non-human primates to create genetic model animals of single-gene disorders beyond Rett syndrome, and to use these models to test gene manipulation methods to subsequently correct the genetic defect in vivo; Research to increase the sophistication of data analyses, (e.g., neuroimaging studies); Development of novel tools and methodologies, including imaging tools and assays, single cell analyses and 憃mics, that allow high throughput phenotyping in cell model systems; Improvements in stem cell techniques to study the molecular and cellular basis of mental disorders; Comprehensively using the imaging genetics in patients or healthy control subjects and the neurobiological characteristics in brain bank tissues, to explore the mechanism of common mental disorders (schizophrenia, autism, etc.). Biologically-relevant computational modeling of neural circuit activity that relates to behavior and/or psychological and cognitive processes in mental health and mental disorders. Research focused on the development of an integrative scientific literature that can inform future, neuroscience-based diagnostic systems, consistent withHYPERLINK "http://www.nimh.nih.gov/research-priorities/rdoc/index.shtml"NIMH抯 Research Domain Criteria爄nitiative. Such studies should include the following elements: Primary hypotheses based on one or more of the defined HYPERLINK "http://www.nimh.nih.gov/research-priorities/rdoc/development-and-definitions-of-the-rdoc-domains-and-constructs.shtml" RDoC domains and constructs; Multiple units of analysis (i.e., genes, molecules, circuits, physiology, behavior, and self-report); Recruitment methods and eligibility criteria that are likely to yield a broad range of severity of the symptoms or problems to be explained, spanning healthy to symptomatic individuals, and avoiding recruitment based strictly on diagnostic criteria; A dimensional approach to data analysis which does not focus only on the extremes of the constructs under investigation.燦ovel, data-based (rather than diagnosis-based) groupings of individuals are acceptable. Research focused on the neurodevelopmental basis of serious mental illness, including: Studies of the prodrome of major mental disorders (e.g. schizophrenia and bipolar disorder); Identification of biomarkers and behavioral markers with predictive values for diagnosis and treatment; Characterization of developmental processes across biological and behavioral systems that give rise to mental illnesses over the lifespan; Determination of sensitive periods and specific factors that modify typical and atypical mental health trajectories; Identification of early biological and environmental risk and protective factors for serious mental illness; Studies of autism, particularly those focused on genomics or early biomarkers, early detection, and/or treatment development. Note: Clinical research is permissible under this FOA, but clinical trials are not. Applicants who wish to conduct a clinical trial focused on mental illness should review information about NIMH抯 new direction for clinical trials research and the relevant FOAs atHYPERLINK "http://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/index.shtml"http://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/index.shtml. 燙ollectively, these FOAs define NIMH抯 focus on an experimental therapeutics approach when supporting clinical trial research. NINDS: The NINDS will support novel collaborative research projects in the areas of Parkinson's disease (PD) and related disorders, stroke, epilepsy, and vascular contributions to cognitive impairment. Applicants are advised to refer to NINDS policy regarding rigorous study design and transparent reporting and to incorporate these standards into their proposed research, HYPERLINK "http://www.ninds.nih.gov/funding/transparency_in_reporting_guidance.pdf"http://www.ninds.nih.gov/funding/transparency_in_reporting_guidance.pdf. Research topics include, but are not limited to: Studies in animal models or human subjects to identify genetic and environmental risk factors as well as epigenetic mechanisms in disease or in specific disease subtypes (e.g., PD, intracerebral hemorrhage, intracranial stenosis, small vessel disease or vascular cognitive impairment); Collaborative research that develops, characterizes, validates and utilizes transgenic animal models and large animal models, such as non-human primates in the following areas: Biomarkers of disease mechanisms and progression; Therapeutic targets; Pathophysiological basis of diseases. Collaborative neuroimaging studies for early diagnosis and progression of disease as well as recovery after stroke; Prospective studies on non-motor and cognitive changes in PD and related disorders or cognitive impairment and dementia due to cerebrovascular disease ; Collaborations in database comparison and data sharing as appropriate (e.g., hospital-based and community-based studies of target neurological disorders). Note:燯S applicants who plan to conduct studies on PD and related disorders on US patients should be aware that: All genetic studies are expected to share data via dbGaP (HYPERLINK "http://www.ncbi.nlm.nih.gov/gap"http://www.ncbi.nlm.nih.gov/gap). All laboratory-based PD studies on human specimen and clinical PD biomarker projects, including imaging studies, must be compliant with the PD Biomarkers Program (PDBP) requirements (HYPERLINK "http://grants.nih.gov/grants/guide/notice-files/NOT-NS-11-020.html"http://grants.nih.gov/grants/guide/notice-files/NOT-NS-11-020.html). Specifically, some human biological samples collected under this program may be required to be deposited in the NINDS repository as stated inHYPERLINK "https://grants.nih.gov/grants/guide/notice-files/NOT-NS-15-046.html"https://grants.nih.gov/grants/guide/notice-files/NOT-NS-15-046.html. In addition, all such projects must utilize the PDBP Data Management Resource (DMR) when sharing clinical, imaging and biological data. A detailed plan for data sharing via the DMR is expected to be included in the data sharing plan. When planning, applicants should take into consideration the above policies, and also engage the approval process in China for international sharing of the biological samples and genetic data as appropriate. HIV/AIDS and Co-Morbities: Priority HIV/AIDS topic areas include: Treatment: Improved treatment outcomes, including: Developing and testing novel therapeutic approaches combining virologic-, immunologic-, and cellular-based therapies. Implementation research to ensure early initiation of treatment, adherence to treatment regimens, retention and engagement in these services, and achievement and maintenance of optimal prevention and treatment responses. Prevention: Reducing incidence of HIV/AIDS, including: HIV phylogenetics: Novel applications to identify hotspots of transmission, phylogenic and epidemiologic analyses of HIV dynamics and models of transmission. Vaccine research: AIDS vaccine candidates, including but not limited to identification of candidate novel immunogens, novel adjuvants, or initial characterization of high-risk populations for possible participation in future clinical trials of AIDS vaccines or combination prevention strategies. Co-Morbidities: Improved prevention or treatment of HIV-associated comorbidities, co-infections, and complications, including: Tuberculosis(basic as well as clinical research): Pathogenesis of TB/HIV co-infection, evaluating biomarkers to predict TB disease outcomes (including risk of activating latent infection), and pre-clinical development of novel immune-based therapeutic and prevention modalities for TB/HIV co-infection and disease. Non-infectious comorbidities: Complications associated with long-term HIV disease and antiretroviral therapy, such as cardiovascular and metabolic disorders, neurologic and neurocognitive disorders, and conditions associated with premature aging. AIDS-related malignancies:燬tudies that optimize the diagnosis, prevention and treatment of HIV-associated cancers, including development of biomarkers for early detection, progression, or response to treatment of HIV-associated cancers. Particular interest in virally associated malignancies such as Kaposi sarcoma, lymphoma, and cervical cancer. Cross-Cutting Topics: Other cross-cutting topics include basic research that underpins the development of strategies for the areas listed above; studies focusing on reducing health disparities in the incidence of new HIV infections or in treatment outcomes of people living with HIV/AIDS; and training. Research involving human subjects (clinical research) is permitted under this FOA. For the NIH definition of clinical research versus clinical trials, please see: HYPERLINK "http://funding.niaid.nih.gov/researchfunding/sci/human/pages/default.aspx" http://funding.niaid.nih.gov/researchfunding/sci/human/pages/default.aspx. Note:燼pplicants and collaborating partners are expected to adhere to NIH regulations for the conduct of research involving human subjects and vertebrate animals. Unlike a standard R01 application, preliminary data are not required under this FOA; however, supporting evidence for past productivity, proposed approach, and techniques should be included. Scope of research or activities NOT supported under this FOA: Any clinical trial including clinical trials of drugs, biologics, or diagnostics (see NIH definition of clinical trials in theHYPERLINK "http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf"Application Guide SF424). For NIH definitions of clinical research vs. clinical trials, please seeHYPERLINK "https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-015.html"https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-015.html. Research involving Select Agents (see 42 CFR 73 for the Select Agent list; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant pathogens). Note:燜or further information on the U.S.-China Program for Biomedical Collaborative Research please visit the following website for general information and questions and answersHYPERLINK "http://www.niaid.nih.gov/researchfunding/qa/Pages/revniaid.aspx" \l "indiv"http://www.niaid.nih.gov/researchfunding/qa/Pages/revniaid.aspx#indiv. |~ 7 M]$$筱站u]uH]u]u]Hu]u)h-K`h顄B*CJKHOJQJ^Jph333/h-K`h顄5丅*CJKHOJQJ\乛Jph333-h-K`h顄B*CJKHOJQJ^JaJph3333h-K`h顄5丅*CJKHOJQJ\乛JaJph333/h-K`h顄5丅*CJKHOJQJ\乛Jph333-h(L5丅*CJKHOJQJ\乛JaJph333hh"K5丆JOJaJhh5丆JOJaJo(h75丆JOJaJo( ~ 8 B; 30i$ &Fd#-D1$M [$\$a$gd顄$d#-D1$M a$gd顄$-D1$M a$gd?]n$d-D1$M a$gd(Lgd7x_( 9K$ &Fd#-D1$M [$\$a$gd顄$ &Fd#-D1$M [$\$a$gd顄$d#-D1$M a$gd顄$ &Fd#-D1$M [$\$a$gd顄zq$ &Fd#-D1$M [$\$a$gd顄$ &Fd#-D1$M [$\$a$gd顄$ &Fd#-D1$M [$\$a$gd顄$d#-D1$M a$gd顄 1!!"9""",#L###$$ &Fd#-D1$M [$\$a$gd顄$ &Fd#-D1$M [$\$a$gd顄$d#-D1$M a$gd顄$ &Fd#-D1$M [$\$a$gd顄 $$0$1$3$4$D$E$F$J$P$Q$^$$$$$%%***F+G+f+g+++c,d,,,11櫨姬櫨艱加杓予蛹徏訃儑n嚰R糝nR紡6jh-K`h6B*CJKHOJQJU^JaJph333)h-K`h顄B*CJKHOJQJ^JphB嬍h6jh6U/h-K`h顄5丅*CJKHOJQJ\乛Jph333)h-K`h顄B*CJKHOJQJ^Jph-h-K`h顄B*CJKHOJQJ^JaJph333)h-K`h顄B*CJKHOJQJ^Jph333-h-K`h顄B*CJKHOJQJ^JaJph $a$$$$ %/%K%%%&&[''d(()b*t++$ &Fd#-D1$M [$\$a$gd顄$d#-D1$M a$gd顄$ &Fd#-D1$M [$\$a$gd顄+,,-./i//\00>11445&6W6$ &Fd#-D1$M [$\$a$gd顄$d#-D1$M a$gd顄$ &Fd#-D1$M [$\$a$gd顄1222031333445555!6"6;:@:A:::;;2;3;;;><?<<<===f=g===i????2A=A0C>C癈糃紺霥E鉋櫨飼瞬髓氳飼瞬髓氂杷撬菜杷撬菜櫨飼瞬髓氳氳氳氳傆鑲/h-K`h顄6丅*CJKHOJQJ]乛Jph333/h-K`h顄5丅*CJKHOJQJ\乛Jph333)h-K`h顄B*CJKHOJQJ^JphB嬍h6jh6U)h-K`h顄B*CJKHOJQJ^Jph333-h-K`h顄B*CJKHOJQJ^JaJph3333W6u7&8X8m8899;::8;<=>i???$ &F d#-D1$M [$\$a$gd顄$d#-D1$M a$gd顄$ &Fd#-D1$M [$\$a$gd顄$ &Fd#-D1$M [$\$a$gd顄??U@2AjAB0C癈霥鉋?GoH稩ZJKWK.M$ &F"d#-D1$M [$\$a$gd顄$d#-D1$M a$gd顄$ &F!d#-D1$M [$\$a$gd顄$ &F!d#-D1$M [$\$a$gd顄鉋鼸﨓?GTGIIjIkI碔礗稩糏絀KVK誎諯譑1L2LILJL昄朙錖鍸)M*M翸肕萂蒑繅唬粐粐r嚮Ｒ唬灰jfjrj籮fjrj籖Ｒ'hB*CJKHOJQJ^JaJph333h6jh6U)h-K`h顄B*CJKHOJQJ^JphB嬍6jh-K`h6B*CJKHOJQJU^JaJph333/h-K`h顄5丅*CJKHOJQJ\乛Jph333-h-K`h顄B*CJKHOJQJ^JaJph333)h-K`h顄B*CJKHOJQJ^Jph333/h-K`h顄6丅*CJKHOJQJ]乛Jph333 .M肕OOOOOO O"O#O$O%Ogd$刪d#-D1$M [$\$^刪a$gd顄$ &F"d#-D1$M [$\$a$gd顄蒑uNvN蘊蚇OOOOOOOOO O!O$O%O栲蔦青璋ààààh3fjh3fU-h顄h顄B*CJKHOJQJ^JaJph333)h-K`h顄B*CJKHOJQJ^JphB嬍h6jh6U-h-K`h顄B*CJKHOJQJ^JaJph3336182P:p"K皞. 捌A!"#悹$悹%癝班惄j666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nHsH tHJ`J"Kck噀$1$a$ CJKH_HaJmH nHsH tH$A $ 貫祂=刉[SOBiB0nf恏贗3縗`?/[G歿\!-跼k.搒曰..椃碼嬋?PK!ブх6_rels/.rels剰蟡0囷吔冄}Q頤%v/C/(h"脎O 劋秣=畫旂毆免C?薶醰=偵叅%[xp啠{鄣_糚眩<10堎O糝瓸d焉襃E4b$q_槥6L籲R7`畯ㄉ趁0虨O,錏n7擫i鋌〃/鉙綈╡械根鑄PK!kytheme/theme/themeManager.xml蘉 @醹愘7c(Eb菜CA菭覠圩邈7蕪諞K Y, 奺.埛饇,ㄚH,l崆駢x紗逫萻Q}#諓叚遞值+!,較$j=婫W櫨)釫+& 8PK!mQtheme/theme/theme1.xml靁MoE#F{oc'vGuh覨盵糟x=逎zvg53Nj廐H垈z飴昛 $石I)*E阓酀欇鮊&IA!裎>秣羌3緓镹男>掤擱U蟇L0斈屵嚦z迃rx鰾脅稔h9T8奣/魁煜?鍃Y雒'蟸3S琦棌~蜩鶅O_|w)馉鎘圚t=乤+d NG1-Rl苼1諶J鴚T锠疢1Kｃ柩"o he浪撣幝絇L-憒%絎臙甴Y7'qP.\L姼=岟薲穛炷3I爋fi墸.帽墘BRb-J款P_p蒅茛▍i㎏鷗郿訉h汧梚櫷o7;7Q嫵2染媱珼>a/銐翾>嶺厭W 藬霱卂膗H剄)薶胺+:Vi豾4r態裶汐橌"r嫃!帓2l徠a麃C奲此U|嚮!8^顩8>軤仯,A魶壭眲V韙鄨讕厏ls囔14犁_=,澀返o聻TV 跥陲"苧鎎H唼灮'.4熯x薜躻-戲蹺鮸褾;氕衯躑`嘼3"G'e\昮H柊O話ㄩ恬愪'$劘i_wp伬 >*靺8魂i&丩Y%\鋁,楎謝視=矚伭壵阱綔r6f 提3儲淭厥厰)橗:陋ZK誏玸ゅ&C鏜兣軟0 [浪玴@註醏j扣7媺耏咹唜Hi葷cT5A蕆跑@顢腍驇馴AZC硙i' RQ\m伕,zo,僩Q襲{Y\,Nψ/=溷ら嵿L_.跆嘫7C6韽-fS宄h62密"5咍麥罭H凾[X65太4X%Y龡豚殖2纅鷎h輩紳痠~tCKF#猥b+趙1m鑵4`眹!:U翞!昿5a:倊{4韒笫m蝘o萎c杽8m泛D矹秔S槍姍豓1鋣?#S奿?3E'pS2疳W`る甸q]( ┻08樲w別 n撏A鯴[s枃)k8皓= Aa?R d趻刪c楿詠瞬d)#換ueb恾滿捷C!ず&i0福>4魫S7鋥z蟣F箎4sKvUKo瘸椒h垀1砵YU奧V蠬塔5U8錠k;譁潘鮈9堚寂皹D 荀 ?*|FL 迪鳡"A3兇伂>g類dm2iV值殍そ杕謌<殞r8[kv抶熞蠃p鎶sj,潩z傴礭[鑚堨叆Qv11縤u鈨-高0%M2羙J描3u舘%覎PK! 褠煻'theme/theme/_rels/themeManager.xml.rels剰M 0匃倃oo雍&輬協勪5 6?$Q祉 ,.嘺緳i粭澤c21h:闀q毩m胳嶡RN壻;d癭値o7g慘(M&$R(.1榬'J摐袏T鶂8V"＆A然蠬鱱}狇|$絙{朠除8塯/]As賲(⑵銻#洩L蔥漢倪PK-!倞[Content_Types].xmlPK-!ブх6+_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!mQtheme/theme/theme1.xmlPK-! 褠煻' theme/theme/_rels/themeManager.xml.relsPK] %Fl $$1鉋蒑%O(-035$+W6?.M%O)*+,./124!F"f""c##)0**,,!-12222>334f44@j@碄諦1CIC旵錍)DuE蘀F%FX晫X晙X晫X晫X晫X晫X晫X晙X晫X晫X晫饎餚$ #咥臕@餒 0( 饞0( 養 S ? OLE_LINK91 OLE_LINK92 OLE_LINK99OLE_LINK100 OLE_LINK97 OLE_LINK98 OLE_LINK95 OLE_LINK96 OLE_LINK67 OLE_LINK68 OLE_LINK61 OLE_LINK62 OLE_LINK71 OLE_LINK72 OLE_LINK88 OLE_LINK89 OLE_LINK90$$33FFQQ``&F $03DFJQ^``&Ffx&lt}# . ; J ,9R^R[mvy$&LMZ"#%%%%&"&#&2&...<.m////////v000011172i666'7)7I7j8{8}88_9|9~99X::::;< <'<<<<<?礍FFFFFF F"F&F8KK] a!"#?禓zC-DFFFFFF F"F&F338LF&F" pf3`Y3;剚製酔6鏣 |P{鰥Mo 0.{zdNk釷勝< j槳t雝&0;釾1D'r$鴲舩- j艄(2?3吞?]} & 0 2 3 : !6"000 00 0000006:>兀﨑 =@\]^$([{ 0 0000000Y;[個鬍鬍2HX $P2!xx O浌(weiqin)nsfcfile@nsfc.gov.cn" !鄥燆鵒h珣+'遲04 px $,魏芹(weiqin)Normal.dotmnsfcfile@nsfc.gov.cn2Microsoft Office Word@F#@跔諱@跔諱v ;脹諟.摋+,D脹諟.摋+, X`lt|#鬍 8@_PID_HLINKSABb?@http://www.niaid.nih.gov/researchfunding/qa/Pages/revniaid.aspxindiv9}Dhttps://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-015.htmlAOhttp://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdfRSJhttp://funding.niaid.nih.gov/researchfunding/sci/human/pages/default.aspx+Dhttps://grants.nih.gov/grants/guide/notice-files/NOT-NS-15-046.htmle*Chttp://grants.nih.gov/grants/guide/notice-files/NOT-NS-11-020.html)- http://www.ncbi.nlm.nih.gov/gap>A Hhttp://www.ninds.nih.gov/funding/transparency_in_reporting_guidance.pdf]http://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/index.shtmlIvhttp://www.nimh.nih.gov/research-priorities/rdoc/development-and-definitions-of-the-rdoc-domains-and-constructs.shtmlW=http://www.nimh.nih.gov/research-priorities/rdoc/index.shtml !"#$%&'()*+,-./012345689:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvxyz{|}~Root Entry F耭諱1Table7WordDocument8lSummaryInformation(wDocumentSummaryInformation8CompObju F#Microsoft Office Word 97-2003 文檔 MSWordDocWord.Document.89瞦